Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Xiangcai Fund has a significant holding in Tiger Med, with the Xiangcai Changxing Flexible Allocation Mixed A Fund (009169) holding 20,900 shares, representing 4.73% of the fund's net value, making it the third-largest holding [2][5]. - The fund has realized a floating profit of approximately 53,100 CNY today and a total of 67,700 CNY during the three-day price increase [2][5]. - The Xiangcai Changxing Flexible Allocation Mixed A Fund was established on April 23, 2020, with a current size of 9.6681 million CNY. Year-to-date, it has incurred a loss of 5.96%, ranking 7640 out of 8898 in its category, while it has achieved a 7.24% return over the past year, ranking 5586 out of 8181 [2][5]. Fund Manager Performance - The fund managers of Xiangcai Changxing Flexible Allocation Mixed A are Che Guanglu and Bao Jiamin. Che has a tenure of 14 years and 30 days, managing assets totaling 489 million CNY, with the best fund return of 54.67% and the worst return of -40.29% during his tenure [3][6]. - Bao has a tenure of 2 years and 24 days, managing assets of 662 million CNY, with the best fund return of 60.96% and the worst return of -12.82% during her tenure [3][6].